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ttp://dx.doi.org/10.1016/j.jmoldx.2012.09.006Genomic abnormalities, such as deletions in 11q22 or 17p13, are associated with poorer prognosis
in patients with chronic lymphocytic leukemia (CLL). We hypothesized that unknown regions of copy
number variation (CNV) affect clinical outcome and can be detected by array-based single-nucleotide
polymorphism (SNP) genotyping. We compared SNP genotypes from 168 untreated patients with CLL
with genotypes from 73 white HapMap controls. We identiﬁed 322 regions of recurrent CNV, 82 of which
occurred signiﬁcantly more often in CLL than in HapMap (CLL-speciﬁc CNV), including regions typically
aberrant in CLL: deletions in 6q21, 11q22, 13q14, and 17p13 and trisomy 12. In univariate analyses, 35
of total and 11 of CLL-speciﬁc CNVs were associated with unfavorable time-to-event outcomes, including
gains or losses in chromosomes 2p, 4p, 4q, 6p, 6q, 7q, 11p, 11q, and 17p. In multivariate analyses, six
CNVs (ie, CLL-speciﬁc variations in 11p15.1-15.4 or 6q27) predicted time-to-treatment or overall
survival independently of established markers of prognosis. Moreover, genotypic complexity (ie, the
number of independent CNVs per patient) signiﬁcantly predicted prognosis, with a median time-to-
treatment of 64 months versus 23 months in patients with zero to one versus two or more CNVs,
respectively (PZ 3.3  108). In summary, a comparison of SNP genotypes from patients with CLL with
HapMap controls allowed us to identify known and unknown recurrent CNVs and to determine regions
and rates of CNV that predict poorer prognosis in patients with CLL. (J Mol Diagn 2013, 15: 196e209;
http://dx.doi.org/10.1016/j.jmoldx.2012.09.006)Supported by a European Hematology Association and American Society
of Hematology grant (C.D.S.), CLL Global Research Foundation grant
(C.D.S. and L.V.A.), Commonwealth Foundation for Cancer Research and
Mr. and Mrs. William H. Goodwin, Jr., grants (L.V.A.), and National
Cancer Institute grant R01CA123252 (L.V.A.).Several recurrent genomic abnormalities have been identi-
ﬁed in chronic lymphocytic leukemia (CLL) using tradi-
tional cytogenic methods and had prognostic importance.1,2
For example, deletions in chromosome 11q22 (10% to 20%
of CLL cases), which includes the ataxia-telangiectasia
mutated (ATM) gene, or 17p13 (3% to 5% of CLL cases),
which includes the tumor protein p53 (TP53) gene, have
been associated with rapid disease progression, treatment
resistance, and inferior survival in patients.1e5 Thus, ﬂuo-
rescence in situ hybridization analysis of interphase nuclei
using a panel of probes is commonly part of the clinicalstigative Pathology
.workup of CLL cases at diagnosis of CLL.1,6 In addition to
the common recurrent chromosomal gains and losses, the
presence of balanced or unbalanced translocations and
cytogenetic complexity (three or more abnormalities) have
been associated with shorter treatment-free and overall
Table 1 Clinical and Laboratory Characteristics of 168 Subjects
Characteristics Absolute value %
Age at sample (years)* 58 (27-83)
Ethnic origin
White American 153 91.1
African American 8 4.8
Hispanic 6 3.6
Asian 1 0.6
Sex
Male 110 65.5
Female 58 34.5
Rai stage
2 132 78.6
3 36 21.4
WBC at sample date (109/L)* 76.2 (7.9-372)
IGHV somatic mutation status
Mutated 90 53.6
Unmutated 76 45.2
Not available 2 1.2
B2M (mg/L)
4 122 72.6
>4 46 27.4
Median (range) 3.3 (1.3-7.8)
ZAP70 expressiony
Positive 73 43.5
Negative 73 43.5
Not available 22 13.1
CD38 expression (%)z
<30 117 69.6
30 45 26.8
Not available 6 3.6
Light chain use
k 104 61.9
l 58 34.5
Not available 6 3.6
FISH positivity (hierarchical model)
Del13q as sole abnormality 35 20.8
Trisomy 12 21 12.5
Del11q 17 10.1
Del17p 6 3.6
Normal 32 19.1
Not available 57 33.9
Follow-up (months)*
Diagnosis to sample (N Z 168) 30.1 (0.0-211.5)
Diagnosis to ﬁrst treatment
(N Z 144)x
34.0 (0.7-211.5)
Diagnosis to ﬁnal follow-up
(N Z 168){
138.0 (0.7-271.3)
Sample to ﬁnal follow-up (N Z 168){ 72.6 (0.7-271.3)
*Data are given as median (range).
yThe expression of ZAP70 was analyzed by either immunohistochemistry (96
patients) or ﬂow cytometry (50 patients). By ﬂow cytometry, patients were
designated ZAP70 positive if expression was 20% in CD19-positive cells.
zImmunophenotypic analysis of CD38 expression was assessed on bone
marrow for 145 patients and on peripheral blood for 17 patients for whom
bone marrow was unavailable.
xThe time from diagnosis to ﬁrst treatment was assessed only for the
cohort of 144 patients who have received treatment as of the last follow-
up. The median was computed using Kaplan-Meier estimates.
{Follow-up times are estimated using the reverse Kaplan-Meier method.
FISH, ﬂuorescence in situ hybridization; WBC, white blood cell.
Copy Number Variation in CLLsurvival (OS).2,7e9 Furthermore, the acquisition of new and
high-risk abnormalities during the clinical course of disease
can render CLL B cells resistant to therapy.10,11 These data
indicate that genomic instability is common in CLL, and
that genetic abnormalities evolve over time, with a subset
of changes that correlate with therapeutic resistance and/or
prognosis.
Modern array-based genomic technologies, such as array
comparative genomic hybridization and single-nucleotide
polymorphism (SNP) genotyping, allow rapid and sensitive
identiﬁcation of small DNA copy number changes that
are beyond the resolution of conventional cytogenetic tech-
niques. For example, we and other researchers have demon-
strated that bacterial artiﬁcial chromosome and
oligonucleotide-based array comparative genomic hy-
bridization allow the identiﬁcation of novel recurrent
genomic imbalances in CLL involving chromosomes 5q, 2p,
8, 19, and 22.12,13Although the average resolution of bacterial
artiﬁcial chromosome arrays is approximately 1 Mb,
commercially available SNP arrays offer the possibility of
genome-wide DNA genotyping at a mean resolution of
<1000 bp by assessing thousands or millions of SNP loci per
patient. Several groups have evaluated such SNP arrays as
a screening tool for copy number abnormalities in various
types of cancers. SNP arrays applied to CLL have identiﬁed
acquired chromosomal imbalances in 66% to 82% of inves-
tigated cases.14e18 However, the interpretation of results from
high-resolution DNA microarrays, especially without
comparison of tumor to matched nontumor DNA, can be
challenging. In particular, SNP arrays detect constitutional
copy number variants and allelic polymorphisms, which tend
to be smaller (median, approximately 150 kb) than acquired
genomic aberrations in tumors.19 It is conceivable that both
acquired and constitutional copy number changes, both
included in the term copy number variation (CNV) herein,
provide a genetic advantage or disadvantage to leukemic
cells, and contribute to disease stage and clinical outcome.
Considerable evidence from family and case-control studies
suggests a nonexclusive, but presumably polygenic, predis-
position for CLL by the presence of DNA variants in distinct
susceptibility loci, such as 2q37.3, 8q24.21, 15q21.3, and
16q24.1.20e22
In the current study,we assessed total CNVbygenome-wide
SNPgenotyping in 168 previously untreated patientswithCLL
using the Illumina610Quadv1 BeadChips (Illumina Inc., San
Diego, CA).We developed analytical methods that allow us to
determine acquired and constitutional CNVs associated with
CLL, and to use the genome-wide copy number data for
time-to-event outcome prognostication, without the avail-
ability of matched nontumor DNA. We hypothesized that
CNVs acquired by CLL cells or inherently involved in CLL
biological characteristics, are detected more frequently in SNP
genotypes frompatientswithCLL than in SNPgenotypes from
healthy HapMap individuals who had been assessed on the
same array platform. Furthermore, we hypothesized that any
CNVs of biological interest in CLL should be associated withThe Journal of Molecular Diagnostics - jmd.amjpathol.org 197
Figure 1 Cumulative SNP genotype in 168 patients with CLL. Loci of copy number abnormalities identiﬁed as autosomal gains are depicted in green; losses
are depicted in pink. Chromosome G-banded ideograms are demonstrated at an approximately 700-band level of resolution. The heights of gains and losses
along the horizontal axis are scaled proportionally to the square root of the number of cases with the corresponding abnormality. Centromeres, repeated
sequences, and constitutive heterochromatin are indicated in red, light blue, and dark blue, respectively.
Schweighofer et alclinical time-to-event outcomes. We calculated CLL-speciﬁc
CNVs as segments that were identiﬁed with statistical signiﬁ-
cance more frequently in patients with CLL than in HapMap
controls. These segments included known recurrent abnor-
malities in chromosomes 2, 6, 11, 12, 13, and 17, as well as
previously unknownCNVs inCLL.Byusing either all orCLL-
speciﬁc CNV, we designed multivariate models that deter-
mined individual CNVs and increasing levels of genotypic
complexity to predict time-to-event outcomes independent of
established markers of prognosis.Materials and Methods
Sample Collection, Puriﬁcation, and Clinicopathologic
Characterization
Between August 17, 2000, and December 15, 2008, with
informed consent, we collected peripheral blood samples
from 176 previously untreated patients with CLL at The
University of Texas M. D. Anderson Cancer Center, Hous-
ton. The study was approved by the Institutional Review
Board and conducted according to the principles expressed in
the Declaration of Helsinki. During sample workup and data
analysis, we removed eight cases because of false diagnosis
(n Z 1), false treatment status (previously treated; n Z 3),
double collection (nZ 1), or poor genotype data quality (nZ
3). All remaining 168 CLL cases had morphological features198of CLL and met the diagnostic criteria established by the
International Workshop on CLL.6 Clinical and routine
laboratory data were obtained by review of the medical
records. The somatic mutation status of immunoglobulin
heavy chain variable region (IGHV) genes and ZAP70
expression, measured by either ﬂow cytometry or immuno-
histochemistry, were assessed on blood or bone marrow
samples, according to established protocols.23e25 Fluores-
cence in situ hybridization analysis for common abnormali-
ties associated with CLL was performed on interphase nuclei
obtained from cultured bone marrow cells using a probe
panel designed to detect deletions of 11q22.3 (ATM),
13q14.3 (D13S319), 17p13.1 (TP53), and trisomy 12
(12p11.1-q11), according to the manufacturer’s instructions
(Abbott Molecular, Abbott Park, IL). The CLL immuno-
phenotypes were scored as either typical or atypical, as
previously described.26,27 The CLL cells were enriched by
negative selection and processed as previously described.28
Enriched cell preparations contained 95% CD5þ/CD19þ
copositive CLL cells, assessed by ﬂow cytometry.
SNP Genotyping Analysis
Genomic DNA was extracted from enriched CLL cells
using DNEasy spin columns (Qiagen, Valencia, CA). We
performed SNP genotyping using Illumina Inﬁnium high-
density DNA Analysis BeadChips (HUMAN610-QUADv1;jmd.amjpathol.org - The Journal of Molecular Diagnostics
Figure 2 A: Relative frequencies of recurrent
segments of CNV in 168 patients with CLL versus
73 white HapMap individuals, based on their
minimally deleted/gained region by SNP genotyp-
ing. Eighty-two autosomal CNVs identiﬁed as
signiﬁcantly more frequent in patients with CLL
than in HapMap individuals are indicated in red
(c2 test). Segments of CNV identiﬁed as signiﬁ-
cantly more frequent in HapMap individuals than
in patients with CLL are indicated in blue.
Segments identiﬁed as equally frequent in both
groups are indicated in gray. B: Frequency of
recurrent CLL-speciﬁc CNVs per patient. CEU,
standard HapMap designation of Utah residents
with Northern and Western ancestry (ie, white).
Copy Number Variation in CLLIllumina Inc., San Diego, CA), according to the manu-
facturer’s instructions. These arrays provide whole genome-
wide coverage by 620,901 tag and nontag SNPs and
additional CNV-targeted probes, with a median spacing of
2.7 kb (mean, 4.7 kb). Brieﬂy, for each CLL case, 200 ng
of DNA was denatured and isothermally ampliﬁed at 37C
for 24 hours. The ampliﬁed product was enzymatically
fragmented, precipitated, resuspended, and hybridized onto
the chip overnight. After allele-speciﬁc, single-base exten-
sion of bead- and sample-bound primers, extension products
were ﬂuorescently stained and assessed using the Illumina
BeadArray Reader (Illumina Inc.).
SNP Copy Number Data Analysis
BeadChip readings derived from 225 HapMap controls
assessed on Human610-Quadv1 BeadChips were down-
loaded from the Gene Expression Omnibus (http://www.
ncbi.nlm.nih.gov/geo; accession number 17205, 73 CEU
samples; accession number17206, 75 CH þ JP; accession
number 17207, 77 YRI). Raw BeadChip data from 168
patients with CLL and 225 HapMap controls were pre-
processed to decode SNP/probe positions and generateThe Journal of Molecular Diagnostics - jmd.amjpathol.orggenotype calls, log R ratio, and B-allele frequency (BAF)
estimates using Illumina GenomeStudio, version 2010.2
(Illumina Inc.). Intensity data for each chromosome per
patient were renormalized and segmented in R by
applying circular binary segmentation.29 Each segment
was assigned one of four calls based on the number of
components in the BAF data: double loss (one compo-
nent), homozygosity (two components), balanced (three
components), or unbalanced (four components) hetero-
zygosity. To determine the best ﬁt among these four
possible models, BAF data on each segment were clus-
tered using k-means, with the quality of the clusters
measured by the silhouette width.30 Adjacent segments
were merged if they exhibited statistically equivalent
copy number and identical BAF calls. Final call assign-
ment was performed by pooling segments of log R ratio
and BAF across patients. Gene alignments were per-
formed using the University of California, Santa Cruz,
Genome gateway (http://genome.ucsc.edu; hg18/March
2006/build 36.1 coordinates, last accessed March 17, 2011)
and miRBase for noncoding RNA (http://mirnablog.com/the-
mirbase-sequence-database-release-130, version 13.0/March
2009, last accessed March 17, 2011).199
Table 2 CLL-Speciﬁc Genomic Segments of CNV, Associated with Time-to-Event Outcomes in Univariate or Multivariate Analyses
ID Chr Band Start-end
No. of
SNPs
No. of Pat
sharing MR Start-end MR
P value for
CLL vs HapMap
P value for
TTT univ
GT0042 2 p11.2-p11.1 87872343-91021213 265 7 89757456-89873958 0.0397 0.0810
LT0118 4 p12-q12 48119281-52514330 131 46 49345777-49345777 0.0000 0.0467
GT0081 4 p15.1 31083440-34471356 504 17 33813772-34027766 0.0029 0.0139
LT0193 6 p21.32 32158177-32608988 635 120 32574137-32574137 0.0054 0.0429
LT0221 6 q27 169980638-170557777 138 13 170224848-170224848 0.0333 0.2640
GT0195 7 q21.11 82689044-83177270 151 12 83131205-83133610 0.0109 0.8467
GT0202 7 q31.1 110249344-111251527 267 10 110718711-110764580 0.0185 0.3858
GT0267 11 p15.4-p15.1 3513788-16565390 3597 9 16167919-16285585 0.0242 0.0375
GT0281 11 q22.1 97861584-98426127 151 8 98132117-98212355 0.0316 0.2866
LT0374 11 q22.3-q23.2 107197896-113285988 1094 22 107520009-113107765 0.0007 0.0400
LT0477 17 p13.2-p13.1 6164128-9233788 767 10 6164128-9233788 0.0185 0.5450
(table continues)
Segments that reﬂect the recurrent abnormalities del11q22 and del17p13 are underlined. P < 0.05 values are boldfaced.
Chr, chromosome; DGV, Database of Genomic Variants (http://projects.tcag.ca/variation, last accessed January 1, 2012); multiv, in
multivariate analysis; Pat, patients; univ, in univariate analysis.
Schweighofer et alQuality Control, Statistical Analysis, and Interactive
Web Tool
All clinical and SNP genotyping data underwent visual
inspection. To assess the quality of SNP data after segmen-
tation, we computed the median absolute deviation about the
segment medians. For most samples, the median absolute
deviation ranged between 0.1 and 0.2. As previously noted,
three samples with a median absolute deviation of>0.3 were
removed for poor genotype data quality.c2 Tests were used to
identify CLL-speciﬁc CNV by comparing the frequency of
the abnormality in CLL cases with the frequency in HapMap
control samples. The correlation of genomic CNV with
clinical or biological covariates was assessed using a
Student’s t-test for continuous variables and Pearson’sc2 andTable 3 Genomic Segments of Total CNVs That Were Independent Pre
ID Chr Band Start-end No. of SNPs
No
sh
LT0069 2 q37.1 232274785-232811993 191 1
LT0138 4 q28.3 134301954-134519508 39 13
GT0117 4 q34.3 179314101-180642935 481
GT0140 5 q14.1 80707506-80931112 68
LT0190 6 p21.33 31353098-31408775 111 5
GT0159 6 p21.32 32518405-32619844 113 1
LT0205 6 q12 66565309-67421357 212 1
GT0182 6 q27 167778489-168519816 296
LT0253 7 q35 143445383-143740335 49
LT0293 8 q24.23 137747099-137955330 117
GT0267 11 p15.4-p15.1 3513788-16565390 3597
LT0419 14 q31.3 85454369-85743205 103
LT0503 18 q22.1 61833162-61974746 48 1
GT0398 22 q11.23 21820663-24259550 623
P < 0.05 values are boldfaced.
Chr, chromosome; DGV, Database of Genomic Variants (http://proje
multivariate analysis; Pat, patients; univ, in univariate analysis.
200Fisher’s exact tests for categorical variables. Outcome
parameters (time-to-treatment and OS) were assessed using
the Kaplan-Meier method to estimate survival functions and
the log-rank test. Median follow-up was estimated using the
reverse Kaplan-Meier method, which uses Kaplan-Meier
estimation for patients alive as the event and deaths as
censored observations to deﬁne the time interval between the
origin and last follow-up.31
To construct multivariate models to predict time-to-
event outcomes, we used a two-step process. First, we
performed univariate analyses by applying log-rank testing
and Cox proportional hazards models. Second, after ﬁltering
variables using a lenient criterion on the univariate P values,
we applied a rigorous criterion to determine the ﬁnal model
by using the Akaike Information Criterion (AIC)32 todictors of TTT
. of Pat
aring MR Start-end MR
P value for
CLL vs
HapMap
P value for
TTT univ
2 232413576-232413900 0.0109 0.0691
8 134352228-134352498 0.4121 0.0765
5 180185537-180252886 0.0723 0.0971
5 80759214-80849681 0.0723 0.0337
5 31400561-31400561 0.0083 0.0618
2 32616865-32616865 0.9754 0.0339
7 67079427-67104015 0.3564 0.0116
5 168131062-168334983 0.8435 0.0293
7 143547020-143639837 0.1428 0.0156
7 137897035-137900849 0.6978 0.0473
9 16167919-16285585 0.0242 0.0375
5 85454369-85743205 0.4802 0.0840
2 61881775-61881930 0.6480 0.0005
9 22717669-24259550 0.3653 0.0550
(table continues)
cts.tcag.ca/variation, last accessed January 1, 2012); multiv, in
jmd.amjpathol.org - The Journal of Molecular Diagnostics
HR TTT
univ
P value for
TTT multiv
HR TTT
multiv
P value for
OS univ
Log HR
OS univ
P value for
OS multiv
Log HR
OS multiv
Potential key gene
affected in or near MR
Structural variation
in DGV (MR)
0.48 0.2313 0.59 0.0113 18.17 0.0073 18.33 IGK@ Yes
1.46 0.2080 1.28 0.3826 0.31 0.9217 0.04 DCUN1D4 Yes
0.48 0.0363 0.53 0.8769 0.08 0.9329 0.05 Intergenic Yes
0.68 0.6149 0.91 0.3254 0.33 0.9168 0.04 HLA,DRA, DRB1, and DRB5 Yes
1.45 0.1069 1.74 0.0310 1.09 0.0449 1.01 LOC15449 and DLL1 Yes
1.07 0.5658 1.24 0.0492 17.08 0.0653 17.01 SEMA3E Yes
0.72 0.9682 0.98 0.0272 17.10 0.0671 16.82 IMMP2L and LRRN3 Yes
2.25 0.0489 2.16 0.5502 0.55 0.7026 0.37 SOX6 Yes
1.51 0.3624 1.43 0.0418 17.09 0.0401 17.19 CNTN5 Yes
1.68 0.4967 1.29 0.5310 0.36 0.1561 0.78 ATM No
1.23 0.3525 0.70 0.0182 1.21 0.8683 0.12 TP53 No
Table 2 (continued)
Copy Number Variation in CLLstepwise add or subtract variables. To construct models that
only used existing clinical predictors, we applied AIC to all
clinical predictors with P  0.15 in the univariate analyses.
To construct models that only used CNV predictors, we
applied AIC to all CNVs with P  0.10 in univariate
models. We then generated a summary statistic by counting
the number of CNVs in the ﬁnal AIC model that were
present in each patient, and used the log-rank test to
determine whether this count was an independent predictor
of the time-to-event outcome.
All computations were performed using the survival
package (version 2.36-10) in the R statistical programming
environment (version 2.14.0). The complete set of computer
scripts used to perform the analyses is available at our
website (http://bioinformatics.mdanderson.org/CLL-SNP).HR TTT univ
P value for
TTT multiv HR TTT multiv
P value for
OS univ
Log HR
OS univ
P
O
1.87 0.0917 1.78 0.9761 0.02 0
1.52 0.3805 1.25 0.9453 0.03 0
2.38 0.0208 3.62 0.7178 0.39 0
3.14 0.1987 1.93 0.1804 1.15 0
1.40 0.0869 1.37 0.9952 0.00 0
2.19 0.3749 1.38 0.0738 0.97 0
2.15 0.4902 1.24 0.4691 0.36 0
3.28 0.0220 3.58 0.9838 0.02 0
3.04 0.0290 2.70 0.7718 0.28 0
2.41 0.0099 3.33 0.1668 0.95 0
2.25 0.0489 2.16 0.5502 0.55 0
2.46 0.0648 2.67 0.9711 0.04 0
3.58 0.0011 3.28 0.4746 0.46 0
2.34 0.3668 1.48 0.7092 0.28 0
Table 3 (continued)
The Journal of Molecular Diagnostics - jmd.amjpathol.orgThis website also contains browsable versions of all SNP
data used herein.
Results
Patient Characteristics and Long-Term Follow-Up
The clinical and laboratory characteristics and follow-up
for 168 previously untreated patients with CLL (110 men
and 58 women; median age, 58 years at diagnosis) are pre-
sented in Table 1. When the samples were obtained, most
patients had low- or intermediate-stage disease [132 (78.6%)
Rai stage2 and144 (85.7%)Binet stageA/B].33,34However,
most patients [116 (69.0%)] had at least one unfavorable
prognostic feature (ie, unmutated IGHV somatic mutationvalue for
S multiv
Log HR
OS multiv
Potential key
gene affected
in or near MR
Structural
variation
in DGV (MR)
.9999 0.00 COPS7B Yes
.7228 0.15 None Yes
.2993 1.29 None Yes
.2857 0.93 SSBP2 Yes
.9799 0.01 HLA-B Yes
.0597 1.09 HLA,DRA, DRB1, and DRB5 Yes
.7703 0.14 None Yes
.8373 0.22 KIF25 and FRMD1 Yes
.8375 0.20 CTAGE4 Yes
.0493 1.45 None Yes
.7026 0.37 SOX6 Yes
.6324 0.53 None Yes
.2973 0.71 None Yes
.7672 0.23 CABIN1 and ADORA2A Yes
201
Schweighofer et alstatus, ZAP70 positivity, high CD38 expression, or elevated
serum b-2-microglobulin (B2M) levels). At ﬁnal follow-up,
144 patients (85.7%) had received frontline treatment using
a variety of regimens, predominantly combined chemotherapy
or chemoimmunotherapy [88patients (61.1%)] (Supplemental
Table S1). Forty-two patients (25%) had died. Based on
Kaplan-Meier estimates, the 5-year OS from diagnosis was
90.2% (95% CI, 85.7% to 94.9%).SNP Genotyping Identiﬁes Regions of CNV
Overall, the computational segmentation of genotype data
in 168 patients with CLL identiﬁed 1064 autosomal
segments called as a gain or deletion (del) (Figure 1). After
correcting for oversegmentation by merging adjacent
segments that represented the same large event (gain or
loss) in the same set of patients, we identiﬁed 322 segments
of recurrent CNV, deﬁned as a minimally deleted/gained
region (MR) in a minimum of ﬁve cases (approximately
3%), for further analysis. Visual review of copy number
(log R and BAF) plots revealed that the largest aberrations
were detected in regions known to be aberrant in CLL.
The single largest deletion was identiﬁed in chromosome
6 (90 Mb; 6q14.1-q27), followed by deletions in chromo-
somes 13 (78 Mb; 13q13.3-q34), 11 (46 Mb; 11q14.1-
q24.1), and 17 (22 Mb; 17p11.1-p13.3).1,2 The largest
chromosomal gain, other than trisomy, was identiﬁed in
chromosome 2p (48.9 Mb; 2p16.3-p25.3), followed byTable 4 Cox proportional hazards analyses testing the count of CNV a
Independent segments (nZ
HR 95% CI P variab
Count of CNV as a continuous variable 2.1 1.7e2.7 6.1  1
Count of CNV as a categorical variable
1 CNV 1.9 0.9e4.2 0.0907
2 CNV 3.6 1.6e7.9 0.0014
3 CNV 9.5 4.2e21.7 9.1  1
Count of CNV as a continuous variable
compared to unfavorable cytogenetics
2.3  -
Count of CNV 2.1 1.67e2.59 6.7  1
Del11q22 and/or del17p13 1.6 1.04e2.40 0.0323
Count of CNV as a categorical variable
compared to known prognostic variables
1.7  1
1 CNV 1.8 0.8e3.9 0.1478
2 CNV 2.9 1.3e6.6 0.0103
3 CNV 7.5 3.1e17.8 5.8  1
Unmutated IGHV status 1.9 1.3e2.7 0.0013
Del11q22 and/or dell7p13 1.2 0.8e1.8 0.3899
Lambda light chain use 1.1 0.78e1.6 0.5507
*P-values for the signiﬁcance of addition of the CNV count to clinical variable
statistic.
CI, conﬁdence interval; HR, hazard ratio; n, number of patients; NA, not appli
202gains in 8q (29.1 Mb; 8q23.3-q24.3) and 18q (15.7 Mb;
18q12.3-q21.32). As expected, the most common trisomy
was of chromosome 12. We also identiﬁed trisomies of
chromosomes 15 (one case), 18 (one case), 19 (one case),
and 22 (two cases). There was one case of monosomy for
chromosome 21.
SNP Genotypes of Patients with CLL Differ from Those
of HapMap Individuals
We compared the genotypes obtained from 168 CLL cases
with the genotypes of 73 HapMap individuals of white
descent, the predominant racial category in our CLL data set.
We calculated the relative frequencies of CNVs designated as
segments of gain or deletion and their MR in CLL versus all
HapMap, and in CLL versus white HapMap samples only
(Figure 2A). Abnormal segments were designated CLL
speciﬁc if they were detected signiﬁcantly more frequently in
patients with CLL than in the white HapMap population
(c2 two-sided P < 0.05, corresponding to a false-discovery
rate of 12%). Of 322 nonredundant CNVs, 82 segments
were identiﬁed as CLL speciﬁc (37 gains and 45 deletions,
PZ 2.17 10−11 to 0.0441) (Supplemental Table S2). These
CLL-speciﬁc segments included regions of CNV on each
chromosome, clearly identiﬁed known common acquired
abnormalities inCLL at the expected rates, andwere consistent
with data obtained byﬂuorescence in situ hybridization in bone
marrow from 111 of 168 samples (Supplemental Table S3):s a predictive variable for TTT
14)
Independent CLL-speciﬁc segments
(nZ3)
le
P overall
model
(Likelihood
ratio test) HR 95% CI P variable
P overall
model
(Likelihood
ratio test)
012 2.1  1012 1.5 1.2e1.9 0.0005 0.0006
5.9  1013 0.0023
1.6 1.1e2.2 0.0131
2.2 1.3e3.7 0.0022
08 NA NA NA
1011* 1.1  1012 0.0014* 2.6x105
011 1.5 1.2e1.9 0.0010
1.9 1.2e2.8 0.0032
07* 5.4  1014 0.0709* 1.3  106
1.3 0.9e1.9 0.1424
1.8 1.1e3.0 0.0262
06 NA NA NA
2.2 1.5e3.2 2.0  105
1.5 1.0e2.2 0.0820
1.4 1.0e2.0 0.0526
s was tested using an analysis of deviance and is based on the chi- square
cable; p, p-value.
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Figure 3 Kaplan-Meier curves of time-to-event
outcomes. A: Kaplan-Meier curves describing the
time-to-treatment function in 36 patients with
three or more CNVs versus 57 patients with two
CNVs versus 60 patients with one CNV versus 13
patients with 0 CNVs. Considered in this analysis
were 14 segments of CNV, independently associ-
ated with TTT. B: Kaplan-Meier curves describing
the time-to-treatment function in 20 patients with
two or more CNVs versus 66 patients with one CNV
versus 82 patients without any CNV. Included in
this analysis were three CLL-speciﬁc segments of
CNV, independently associated with TTT. C: Kaplan-
Meier curves describing the survival function in 15
patients with two or more CNVs versus 55 patients
with one CNV versus 98 patients without any CNV.
Considered in this analysis were nine segments of
CNV that independently associated with OS. D:
Kaplan-Meier curves describing the survival func-
tion in 16 patients with one or more CNVs versus
150 patients without any CNV. Considered in this
analysis was only one CLL-speciﬁc segment of CNV
(del6q27) that independently predicted OS. ab.,
abnormality.
Copy Number Variation in CLLdel6q16.3-q21, 7.7% [loss (LT) 0211, 13 patients, P Z
0.0083]; del11q22.3-q23.3, 13.1% (LT0374, 22 patients,PZ
0.0007); del13q12.3-q21.1, 51.2% (LT0405, 86 patients,
P Z 5.8  1014); del17p13.1-13.2, 6.0% (LT0477,
10 patients, PZ 0.0185); and gains (GT) of chromosome 12,
17.3% (GT0299, 28 patients, including 25 with complete
trisomy, PZ 0.0002). CLL-speciﬁc segments were detected in
a minimum of 7 patients (4.2%) and spanned 10 SNPs. The
median number of CLL-speciﬁc CNVs per patient was 10
(range, 3 to 21) (Figure 2B). There was no patient without any
CNV.We identiﬁed no single CNV shared by all CLL samples.
In addition, this analysis identiﬁed 31 regions that were more
common in the HapMap population than in CLL cases.
CNVs in Chromosomes 2, 4, 6, 7, 11, and 17 Are
Associated with Clinical Prognostic Parameters and
Time-to-Event Outcome
Univariate analyses demonstrated that previously de-
scribed prognostic factors, such as IGHV somatic mutation
status, ZAP70 expression, elevated serum B2M or lactate
dehydrogenase level, age, and unfavorable genetics (eg,
del11q22/del17p13 or del6q21/del17p13 by SNP), are
associated with time-to-event outcomes in our data set
(log-rank test) (Supplemental Table S4 and Supplemental
Figure S1).1,34e39 In multivariate analyses, the best model
for time-to-treatment (TTT; P Z 1.5  106) retainedThe Journal of Molecular Diagnostics - jmd.amjpathol.orgIGHV somatic mutation status [hazard ratio (HR), 2.3; 95%
CI, 1.6 to 3.3], del11q22 or del17p13 (unfavorable cyto-
genetic abnormalities) by SNP (HR, 1.5; 95% CI, 1.04
to 2.2), and l light chain use (HR, 1.42; 95% CI, 1.06 to
2.0) as independent predictive variables. The best model for
OS (P Z 9.4  106) retained IGHV somatic mutation
status (HR, 2.2; 95% CI, 1.1 to 4.5), serum B2M level
(categorical; cutoff, 4 mg/L; HR, 2.4; 95% CI, 1.3 to 4.6),
and del6q21 or del17p13 by SNP (HR, 2.7; 95% CI, 1.3
to 5.6).
Next, we determined which of the 322 recurrent CNVs
were associated with the strongest prognostic parameters in
our data set (ZAP70 positivity, unmutated IGHV status, high
serum B2M, and l light chain use), with high CD38
expression or Rai stage, or with time-to-event outcomes. In
univariate analyses (log-rank test), 71 of 322 nonredundant
segments were associated with at least one prognostic
marker, 22 correlated with TTT, and 14 correlated with OS (P
< 0.05) (Supplemental Table S5); 20, 5, and 6 of these
segments, respectively, were CLL speciﬁc. The CLL-speciﬁc
segments associated with time-to-event parameters (Table 2)
included losses in 4p12-q12 (46 patients; key genes, CWH43
and DCUN1D4), 6p21.32 (120 patients; HLA-DR region),
6q27 (13 patients; key gene, DLL1), 11q22.3-q23.2 (22
patients; MR, ATM and other genes), and 17p13.2-p13.1 (10
patients; MR, TP53 and other genes). CLL-speciﬁc gains
associated with TTT or OS were detected in 2p11.1-p11.2203
Table 5 Genomic Segments of Total CNVs That Were Independent Predictors of OS
ID Chr Band Start-end
No. of
SNPs
No. of Pat
sharing MR Start MR
P value for
CLL vs HapMap
P value for
TTT univ
LT0001 1 p36.21 12767427-13614996 102 10 12821696-12836483 0.3031 0.6416
GT0137 5 q13.2 68862825-69475807 105 11 69328189-69379245 0.5663 0.0607
GT0159 6 p21.32 32518405-32619844 113 12 32616865-32616865 0.9754 0.0339
LT0267 8 p22 13620726-13654984 26 5 13620726-13654984 0.0723 0.7886
LT0294 8 q24.3 141086472-141321409 152 10 141189636-141189852 0.0699 0.4621
LT0354 11 p15.4 3383178-3888105 110 5 3588683-3686252 0.0723 0.1159
GT0311 13 q13.2–q13.3 33937199-35109143 303 5 34542952-34877387 0.0723 0.6773
GT0380 20 p11.1 25710186-25971373 64 5 25894996-25897274 0.4773 0.3422
LT0551 22 q11.23 22448589-23491733 260 25 22688572-22715105 0.1200 0.9409
(table continues)
P < 0.05 values are boldfaced.
Chr, chromosome; DGV, Database of Genomic Variants (http://projects.tcag.ca/variation, last accessed January 1, 2012); multiv, in
multivariate analysis; Pat, patients; univ, in univariate analysis.
Schweighofer et al(seven patients; MR, immunoglobulin k light chain locus),
4p15.1 (17 patients; MR, intergenic), 7q21.11 (12 patients;
MR, SEMA3E ), 7q31.1 (10 patients; MR, IMMP2L),
11q22.1 (eight patients; MR, intergenic), and 11p15.1-p15.4
(nine patients; MR, SOX6).
Individual CNVs and CNV Rates per Patient
Independently Predict Time-to-Event Outcome
We determined whether recurrent CNV, which associated
with time-to-event outcomes by univariate analysis, would
do so after adjustment for other known CNV and outcome
predictors in a multivariate analysis. Of 39 recurrent overall
CNVs that showed at least a trend to associate with TTT (P<
0.10), 25 were associated with poorer outcome (HR, >1).
Two of these regions of CNV were biased through co-
occurrence with unfavorable abnormalities in CLL
(del11q22/del17p13) or with trisomy 12 by c2 testing. For
the remaining 23 regions, we used AIC to optimize a multi-
variate Cox proportional hazards model that prioritized 14
segments as independent predictors of TTT (Table 3).
Six of these CNVs (ie, losses in 7q35, 8q24.23, and
18q22.1; and gains in 4q34.3, 6p21.32, and 11p15.1-15.4)
(CLL speciﬁc) added signiﬁcant predictive value as
individual variables to our established clinical model
(P  0.05), after adjusting for IGHV somatic mutation
status, light chain use, and presence of del11q22/del17p13
by SNP. Moreover, the number of CNVs per patient
(either as a continuous or a categorical variable) in the
14 independent segments was identiﬁed as a signiﬁcant
predictor of TTT in multivariate analyses beyond the
statistical effect of the clinical model, including unfavor-
able genetics, IGHV somatic mutation status, and light
chain use (P  1.68  107) (Table 4). Each additional
count of a gain or loss in one of the segments increased
the HR for the patient to require treatment by 2.1-fold
(95% CI, 1.7 to 2.5; P Z 7.8  1016). Patients with
three or more CNVs had an 8.1 times higher risk (95% CI,
3.48 to 18.9) to be treated than patients with no204abnormalities (P Z 2.0  109) (Figure 3A). The median
TTT for patients with zero to one abnormality was 64
months (95% CI, 44.7 to 103.2), compared with 23 months
for patients with two or more abnormalities (95% CI, 17.1
to 33.1) (P Z 3.3  108).
We repeated this analysis beginning only with eight CLL-
speciﬁc segments that demonstrated at least a trend to
associate with decreased TTT in univariate analyses (P <
0.10). After accounting for bias by known common abnor-
malities or mutual dependence, we found an optimal set of
three segments of CNV in 4p12-q12, 6p21.33, and 11p15
that predicted TTT in a multivariate model. The per-patient
count of CNV in these three segments again performed as
a signiﬁcant predictor of TTT as either a continuous (P Z
2.7  104) or ordinal (P Z 0.0029) variable (Figure 3B)
and was independent of the known genetic markers (P Z
0.0014). Included in the clinical model, which incorporated
unfavorable genetics, IGHV somatic mutation status, and
light chain use, the count still demonstrated a statistical
trend for an independent predictive value (P Z 0.0709).
We repeated the same type of multivariate model building
for OS starting with 39 recurrent CNVs associated with OS
in univariate testing (P < 0.10), 14 of which were associated
with a poor outcome. We identiﬁed nine CNVs as inde-
pendent predictors of adverse survival (Table 5), four of
which (losses in 8p22, 8q24.3, and 11p15.4, and gain in
20p11.1) added signiﬁcant value as individual variables to
our clinical model beyond IGHV somatic mutation status,
serum B2M level, and unfavorable genetics (del6q21/
del17p13) (P < 0.0336). The count of CNV in these
segments also signiﬁcantly predicted OS, both as a contin-
uous and a categorical integer, independent of the same
clinical factors (P  3.5  105) (Table 6 and Figure 3C).
None of the predictive segments were CLL speciﬁc. Starting
the analysis with only CLL-speciﬁc CNV associated with
OS, only deletions in 6q27 (LT0221) (Supplemental Table S2)
performed as a signiﬁcant predictor of OS (P Z 0.0093)
(Figure 3D). As a predictor of OS, this segment was inde-
pendent of unfavorable genetics (P Z 0.01734), as welljmd.amjpathol.org - The Journal of Molecular Diagnostics
HR TTT
univ
P value for
TTT multiv
HR TTT
multiv
P value for
OS univ
Log HR
OS univ
P value for
OS multiv Log HR OS multiv
Potential key gene
in MR or overall segment
Structural variation
in DGV (MR)
1.20 0.5141 1.30 0.0309 17.09 0.0914 16.94 HNRNPCL1 Yes
1.91 0.0366 2.09 0.0305 1.09 0.0504 0.99 SMA4 and SERF1A/B Yes
2.19 0.3749 1.38 0.0738 0.97 0.0597 1.09 HLA,DRA, DRB1, and DRB5 Yes
1.15 0.8109 1.13 0.0916 1.19 0.0336 1.59 None Yes
1.32 0.2940 1.51 0.0695 1.12 0.0428 1.28 TRAPPC9 Yes
2.52 0.2153 2.05 0.0117 1.96 0.0211 1.78 ART1/5 and NUP98 Yes
1.22 0.5043 1.38 0.0950 1.18 0.1028 1.16 NBEA Yes
1.59 0.6163 1.27 0.0050 1.87 0.0273 1.44 None Yes
0.98 0.4202 0.82 0.0226 0.88 0.0936 0.67 GSTT1 Yes
Table 5 (continued)
Copy Number Variation in CLLas independent of the clinical model that incorporated
unfavorable genetics, IGHV mutation status, and B2M
(P Z 0.0449).
Discussion
We report one of the largest data sets of CNV in a total of 168
previously untreated patients with CLL, combined with
extensive clinical and laboratory data. Several earlier studies
have provided data on global DNA copy number proﬁling in
CLL cases using SNP-based microarrays. However, unlike
the current study, many of these older data sets were signif-
icantly smaller than the current study, had a shorter follow-up
or limited clinical data, were based on mixed patient cohorts
with respect to treatment status, or were performed using
unenriched blood and/or bone marrow samples, which
decreases the sensitivity to detect abnormalities in small
subclones.14e17,35
For stored tumor samples, one limiting factor in identifying
regions of acquired CNV has been the lack of corresponding
nontumor DNA for comparison. This is particularly true for
tumors collected and processed before the advent of cost-
effective, high-throughput genomic technologies, as were
many of the samples in the current study, or for small biopsy
specimens that lack surrounding normal tissue. Alternative
approaches are needed to analyze genomic data from tumors in
the absence of patient-matched benign tissue. Two studies of
CNV inCLLbySNP genotyping have compared puriﬁedCLL
DNAwithnontumorDNAprepared fromeither puriﬁedT cells
or buccal swabs.14,18 Other studies have identiﬁed abnormali-
ties by either visual inspection of the plots or selection of only
those abnormalities that demonstrated <50% overlap
with copy number events in the Toronto Database of Ge-
nomicVariants (http://projects.tcag.ca/variation, last accessed
January 1, 2012).16,36 In this study, we developed a statistical
approach that addresses the limitation of the lack of nontumor
DNAbycomparinggenotypes frompatientswithCLLwith the
genotypes from healthy white HapMap individuals whose
DNA had been analyzed on the same SNP genotypingThe Journal of Molecular Diagnostics - jmd.amjpathol.orgplatform. Furthermore, we focused our study on identifying
regions of CNV that were associated with time-to-event
outcomes, rather than cataloguing regions of acquired CNV.
This approach shouldﬁlter out array noise (eg, detection errors,
repetitive sequences, or population-speciﬁc genomic poly-
morphisms), but it still allows us to identify new genomic
regions of potential clinical or biological relevance in CLL.
We identiﬁed 322 nonoverlapping genomic segments of
CNV in a subset of at least ﬁve patients (3%). We chose 3%
as a reasonable minimum patient subset of clinical interest
(similar to the incidence of TP53 deletion) in which we
could expect statistically signiﬁcant and clinically relevant
associations in our data set. The 322 segments included 111
gains (34.5%) and 211 losses (65.5%). Consistent with data
provided in studies previously reported, chromosomal los-
ses were more common than gains.14e18 In a recent study
using Affymetrix 6.0 SNP arrays (>900,000 SNP and copy
number probes), Ouillette et al18 identiﬁed 584 different
somatic changes in 255 patients with CLL. Approximately
20% of patients presented without any somatic abnor-
mality. Recurrent somatic abnormalities other than the
common abnormalities were relatively infrequent, occur-
ring in subsets of 6 to 10 patients (2.4% to 3.9%), and
included losses on chromosomes 8p, 10q, 14q, and 18q and
gains on 8q, 17q, and 18p. Abnormalities in these regions
often showed variability in the start and end sites, leading to
more than one minimally deleted or gained region (MR).18
By comparing the 322 genomic segments in CLL to Hap-
Map samples, we identiﬁed three groups of CNV: CNV
equally present in CLL and in HapMap, CNV signiﬁcantly
more frequent in CLL than in HapMap (CLL speciﬁc), and
CNV signiﬁcantly more frequent in HapMap than in CLL.
Among the 82 CLL-speciﬁc segments, we detected well-
established recurrent abnormalities, such as deletions in
6q, 11q, 13q, and 17p and trisomy 12, in the expected
frequencies. Our ﬁnding that some CNVs occur more
frequently in normal HapMap individuals compared with
patients with CLL raises the possibility that some poly-
morphisms may be associated with a decreased risk of205
Table 6 Cox proportional hazards analyses testing the count of CNV as a predictive variable for OS
Independent segments (nZ9) Independent CLL-speciﬁc segments (nZ1)
HR 95% CI P variable
P overall
model
(Likelihood
ratio test) HR 95% CI P variable
P overall
model
(Likelihood
ratio test)
Count of CNV as a continuous variable 2.7 1.8e4.1 1.5  106 3.5  107 3.0 1.3e7.1 0.0133 0.0093
Count of CNV as a categorical variable 3.8  107 NA NA NA
1 CNV 2.6 1.3e5.4 0.0083
2 CNV 7.6 3.3e17.2 1.4  106
Count of CNV as a continuous variable
compared to unfavorable cytogenetics
6.0  106 7.6  107 0.0173* 0.0058
Count of CNV 2.7 1.8e4.1 2.2  106 3.4 1.4e8.4 0.0066
Del6q21 and/or del17p13 1.7 0.8e3.6 0.1630 2.1 1.0e4.5 0.0549
Count of CNV as a categorical variable
compared to known prognostic variables
3.9  106 7.3  1011 0.0449* 1.2  106
1 CNV 3.0 1.4e6.4 0.0036 2.7 1.1e6.7 0.0250
2 CNV 7.6 3.1e18.4 7.4  106 NA NA NA
Unmutated/GHV status 1.7 0.8e3.5 0.1537 2.2 1.1e4.5 0.0278
High B2M 2.1 1.1e4.2 0.0246 2.2 1.2e4.3 0.0147
Del6q21 and/or del17p13 4.0 1.8e9.0 0.0005 2.7 1.3e5.7 0.0104
*P-values for the signiﬁcance of addition of the CNV count to clinical variables was tested using an analysis of deviance and is based on the c2 statistic.
CI, conﬁdence interval; HR, hazard ratio; n, number of patients; NA, not applicable; p, p-value.
Schweighofer et aldeveloping CLL. Larger population-based studies are
needed to test this hypothesis.
Visual inspection of the copy number plots on our website
(http://bioinformatics.mdanderson.org/CLL-SNP) indicated
that gains in 2p and 8q are themost commonly acquiredCNVs
after del6q, 11q, 13q, 17p, and trisomy 12. By using
conventional or high-throughput technologies, researchers
have described gains in 2p as a frequent genomic event in
advanced-stage CLL, and this abnormality has potentially
unfavorable prognostic signiﬁcance. REL and BCL11A
(2p15-p16.1) or MYCN (2p24.3) have been reported as the
genes most frequently gained.14,16,36e38 We identiﬁed
a segment in this region (GT0038, 2p12-16.3) as a CLL-
speciﬁc event in eight patients (PZ 0.0316) (Supplemental
Table S2), with an MR in 2p15-p14. Of these eight patients,
seven presented with an overlap in 2p16.1-p15 that included
REL and BCL11A; six patients shared >6 Mb of gained
chromosomal material that included MYCN and >350 other
genes. Furthermore, four patients also demonstrated losses in
ATM/11q22.3, indicating a potential biological relationship
between gains in 2p and ATM losses. However, we found no
association between gains in GT0038 or gains solely in
BCL11A/REL or MYCN and clinical outcome. Gains in
8q24.21, which lead to overexpression of MYC, have previ-
ously been found in approximately 3%ofCLL cases, andmay
be associated with an unfavorable prognosis.39 We identiﬁed
similar gains in this region in ﬁve patients (CLL-speciﬁc
segment GT0232) (Supplemental Table S2). These gains
were relatively large, with a minimum overlap of 19.1 Mb,
and contained>90 genes. However, we found no association
between gains in 8q and time-to-event outcomes.206Algorithms that attempt to identify MRs using SNP gen-
otyping face major statistical challenges. These challenges
begin with the segment boundaries found when applying
segmentation algorithms one sample at a time. In our data, the
SD of the SNP log ratios is between one-half and two-thirds
of the distance between the expected levels for a single copy
gain or loss. As a consequence, there is inherent uncertainty
in the segment boundaries for individual patients, on the
order of two to three SNPs or 10 to 15KB. This uncertainty is
compounded when intersecting segments from multiple
patients are considered. Statistically, ﬁnding the intersection
requires estimating the extreme values of a distribution (the
left end point is a maximum; the right end point, a minimum),
which is intrinsically more variable than an estimate of the
mean. Estimates of extreme values are not robust because
they can be heavily inﬂuenced by a single outlier. For
example, theMR determined algorithmically for the 8q24.21
gain failed to include MYC because one subsegment for one
patient (CL104) had a median log ratio that was just short of
the cutoff needed to call a gain. The MR determined algo-
rithmically for the 2p15-16.1 gain failed to include REL or
BCL11A because of the inclusion of one patient (CL048) for
whom the evidence for the segment boundary is weak. The
Genomic Identiﬁcation of Signiﬁcant Targets in Cancer
(GISTIC) method improves on the simple intersection of
segments, but this method still relies on the (possibly inac-
curate) results of the individual segmentation algorithms.40
There is substantial room for improvement in statistical
algorithms that combine the raw data with the segments to
identify MR across sets of patients. Meanwhile, visual
inspection of copy number plots is still needed to conﬁrmjmd.amjpathol.org - The Journal of Molecular Diagnostics
Copy Number Variation in CLLrelevant minimally gained or deleted regions. Our website
(http://bioinformatics.mdanderson.org/CLL-SNP) provides
multiple images of both the raw and segmented data to
facilitate visual inspection.
Visual inspection revealed additional regions of CNV
shared by fewer than our cutoff of ﬁve cases. These regions
included 78 events of 1 Mb in 42 patients (25%), and often
appeared to target potential tumor suppressor genes or onco-
genes (eg, PTEN in patient sample CLL213 or hsa-mir-181a-
1/b-1 in sample CLL137) (http://bioinformatics.mdanderson.
org/CLL-SNP), most of them as a single-case event. Patients
with such rare events also tended to have higher overall
numbers of total or CLL-speciﬁc abnormalities, and carried
a deletion in 17p13 signiﬁcantlymore frequently (P 0.0324)
(data not shown), indicating a higher level of genomic insta-
bility in those cases. Thus, our SNParray data demonstrate that
CLL cases exhibit substantial genomic heterogeneity. The
ﬁnding is also consistent with results obtained using next-
generation sequencing technologies, which have shown
many small subsets of patients with CLL who contain muta-
tions in a wide variety of genes.41e43 It is conceivable that
these rare recurrent abnormalities affect the disease outcome in
individual patients and might need therapeutic consideration
in the future, but their clinical relevance is difﬁcult to
characterize.
We identiﬁed previously unknown regions of CNV that
were associated with time-to-event outcomes, and that were
retained in multivariate models of prognosis, independent of
established prognostic markers in CLL. For most of these
CNVs, structural variants in the minimally deleted or gained
region have been described in the Database of Genomic
Variants (http://projects.tcag.ca/variation, last accessed
January 1, 2012). Interestingly, variations in the HLA region
(LT0193 and GT0159; MR, HLA-DR region) demonstrated
signiﬁcant associations with time-to-treatment. The HLA
gene locus comprises a highly polymorphic genomic region
prone to structural changes and recombination, resulting in
a characteristically diverse SNP log R ratio/BAF proﬁle
obtained by array genotyping. In a recent report, Shah
et al44 demonstrated that homozygosity for distinct HLA-A,
HLA-B, HLA-C, or HLA-DR haplotypes, including
HLA-DR5, occurs more frequently in patients with CLL
than in healthy control individuals and is associated with
progression-free-survival. Although we cannot distinguish
single HLA alleles by SNP genotyping, the variation in the
genomic segments we found in this region may reﬂect this
phenotypic bias in HLA haplotypes that characterize CLL,
and may potentially inﬂuence tumor immunogenicity and
immunosurveillance. In particular, a biased presentation of
antigens in patients with CLL carrying distinct HLA
haplotypes might contribute to the clonogenic activation of
CLL cells in the B-cell compartment. Thus, a detailed
analysis of HLA haplotypes in patients with CLL of larger
data sets is desirable to assess this hypothesis.
Because we lacked matched normal DNA samples, we
were unable to distinguish between acquired somaticThe Journal of Molecular Diagnostics - jmd.amjpathol.organd nonsomatic CNV. Nevertheless, we were able to
build multivariate models of predictive value using total or
CLL-speciﬁc CNV detected by the SNP platform. These
models were statistically independent of clinical variables
when we used all CNVs, but were not independent when
we restricted to CNVs that were CLL speciﬁc based on
a comparison with white HapMap samples. The statistical
signiﬁcance also decreased if we included only segments
that contained at least one protein-coding gene or miRNA.
Most previous studies of CLL using SNP genotyping
have focused on CNVs within coding regions. By using
recent builds of Entrez Gene, the University of California,
Santa Cruz, Genome Browser, and miRBase, we found
that 93 (28.9%) of the 322 nonredundant abnormalities
contained no protein-coding or miRNA genes in the
overall segment, and 165 (51.2%) had no known genes
within the MR. Of the 165 segments, 29 were associated
with outcome in univariate analysis, and 10 in multivariate
models. CNV in these segments might include nonsomatic
variation in susceptibility regions within segmentation-
dependent boundaries in our study. Large genome-wide
association studies have demonstrated CLL-associated
SNPs of unknown function in noncoding regions, such as
variations in 2q13 (rs17483466), 11q24.1 (rs735665), and
15q23 (rs7176508).21,45 These regions may contain regu-
latory elements involved in transcriptional activation,
silencing, epigenetic modiﬁcation, chromatin organization,
or unidentiﬁed noncoding RNA genes. Further validation
and biological studies are necessary to elucidate the
signiﬁcance of somatic and nonsomatic variations in non-
coding genomic regions in CLL.
In summary, SNP genotyping of 168 untreated patients
with CLL identiﬁed regions of CNV in segments of chro-
mosomes previously known to be gained or lost in CLL, as
well as new segments of CNV, including loci of suspected
DNA structural variants, associated with clinical and bio-
logical covariates and time-to-event outcomes. By using
a segmentation approach and a focused analysis of outcome-
related CNV, we constructed predictive models that allowed
us to use this information to predict inferior outcome based
on regions of CNV. We found that some of the genomic loci
associated with regions of CNV found in the normal pop-
ulation are highly related with clinical outcome in our data
set of previously untreated patients with CLL.
Genome-wide population studies using high-throughput
whole genome sequencing methods have unveiled millions
of SNPs and copy number changes, including short inser-
tions/deletions present in the general population (The 1000
Genomes Project Consortium).46 Family and epidemiolog-
ical case-control studies have provided evidence for the
role of inherited genetic susceptibility in CLL. Our study
indicates that acquired and nonacquired genomic variants,
including CNV in distinct chromosomal segments, might
affect long-term outcome in patients with CLL. Validation
of our ﬁndings in larger studies, using higher-resolution
technologies (eg, next-generation sequencing), and/or207
Schweighofer et almeta-analyses of genome-wide proﬁling data from several
CLL groups are needed to comprehensively address the
clinical relevance of acquired and common genomic varia-
tion in patients with CLL.
Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.jmoldx.2012.09.006.
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